Navigation Links
Chemo Combo May Help Stave Off Pancreatic Cancer Death
Date:5/11/2011

By Maureen Salamon
HealthDay Reporter

WEDNESDAY, May 11 (HealthDay News) -- A four-drug chemotherapy regimen for deadly pancreatic cancer nearly doubled patients' survival time compared to standard chemotherapy, a new study suggests.

In late-stage trials, French researchers split a group of 342 patients with advanced pancreatic adenocarcinoma, the most common form of the disease, into two groups. Half received gemcitabine, the standard treatment, while the rest received FOLFIRINOX, a four-drug combination of oxaliplatin, irinotecan, leucovorin and fluorouracil.

The median survival time improved from 6.8 months for those in the gemcitabine group to 11.1 months in the FOLFIRINOX group, according to the study, which is published in the May 12 issue of the New England Journal of Medicine. Those in the combination group did suffer greater side effects from treatment, however.

"We explain to the patients the advantages and toxicities of both regimens," said study author Dr. Thierry Conroy, a professor of medical oncology at Nancy University and Centre Alexis Vautrin in Nancy, France. "The FOLFIRINOX regimen was able to stabilize patients longer with improved quality of life and delay degradation of quality of life. Unfortunately, it is still a palliative treatment but able to save months, and sometimes years of life."

Pancreatic adenocarcinoma was the fourth leading cause of cancer deaths in the United States in 2010, the study said, and the five-year survival rate is only 6 percent in both the United States and Europe.

Study participants, whose average age was 61, were still fully active and able to carry out daily activities, and sicker patients were not eligible. The trial was conducted at 15 centers in France during the second phase of the trial and expanded to 48 centers during the third phase of the trial.

Patients discontinued the study at their request or if they experienced unacceptable toxic effects -- which included diarrhea, low blood cell counts and sensory neuropathy -- or evidence of disease progression. One patient from each group died from treatment-related causes, and 273 of the 342 patients had died by the end of the median follow-up period of 26 months.

Dr. Alberto Montero, an assistant professor of medicine at Sylvester Comprehensive Care Center at University of Miami Miller School of Medicine, said the results were "remarkable" because the FOLFIRINOX group experienced such an improved survival rate.

Montero cautioned, however, that a small minority of patients with pancreatic adenocarcinoma match the condition of patients in the study, who were still conducting normal daily activities. Even newly diagnosed patients are often extremely ill, he said, and might not be able to tolerate the combination drugs' toxic effects.

"To see a doubling in survival is impressive," said Montero, also a medical oncologist. "For many reasons, this cancer is very resistant to chemotherapy. I think this trial is a first step."

More information

The U.S. National Institutes of Health has more on pancreatic cancer.

SOURCES: Thierry Conroy, M.D., professor, medical oncology, Nancy University and Centre Alexis Vautrin, Nancy, France; Alberto J. Montero, M.D., assistant professor, medicine, Sylvester Comprehensive Cancer Care Center, University of Miami Miller School of Medicine; May 12, 2011, New England Journal of Medicine


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Genetic information may help predict likelihood of survival following chemotherapy for breast cancer
2. Genomic test shows promise as chemotherapy response, survival predictor for women with breast cancer
3. Most Leukemia Patients Recover From Chemo Brain After Transplant: Study
4. Gene expression predicts chemotherapy sensitivity of triple-negative breast cancer
5. Most patients recover from chemo-brain by 5 years after stem cell transplant
6. RxPONDER trial will evaluate whether gene expression test can drive chemotherapy choice
7. Managing Chemoradiation Side Effects May Prolong Survival
8. Phase 3 trial finds no benefit from atrasentan added to chemo for advanced prostate cancer
9. Minimizing side effects from chemoradiation could help brain cancer patients live longer
10. Immune system may guide chemotherapy for breast cancer
11. New approach to leukemia chemotherapy -- is a cure in sight?
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Chemo Combo May Help Stave Off Pancreatic Cancer Death
(Date:4/28/2017)... ... April 28, 2017 , ... Phytomer USA is pleased to ... 20+ years of experience within the beauty industry, ranging from marketing, retail support, ... high-end cosmetic brands, retail brands and outlets in Canada and New York. As ...
(Date:4/28/2017)... , ... April 28, 2017 , ... Rob Lowe is ... now he has leant his presence to an educational purpose as the host of ... important one being cancer. In a recent episode, the series focuses on thyroid cancer. ...
(Date:4/27/2017)... , ... April 27, 2017 , ... ... Insights in Incentives, Rewards, and Recognition: A Nudge Guide," a groundbreaking analysis of ... field. Offering practical takeaways to apply immediately to IRR programs, the report highlights ...
(Date:4/27/2017)... ... April 27, 2017 , ... Last night, Christine Collins of ... Year for her extraordinary compassion and lifelong dedication to serve others. Since 1997, ... for the prestigious award each year – identifying a CAREGiver who has exemplified ...
(Date:4/27/2017)... (PRWEB) , ... April 27, 2017 , ... Are you ... tragic spike in water-related accidents and drownings during the summer. While most of us ... that these situations occur every day. Very few people are taking the time to ...
Breaking Medicine News(10 mins):
(Date:4/28/2017)...  Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: ... fiscal second quarter ended March 31, 2017, and ... results and updated guidance reflect the contribution from ... completed on February 14, 2017.  For ... $0.51 per diluted share compared to $0.33 per ...
(Date:4/26/2017)... , April 26, 2017 Phoenix Marketing Solutions ... fifteenth year of fulfilling its mission of transforming science into ... highly scrutinized, Phoenix,s innovative approach supports ... community about the latest advances in science and medicine — ... was founded in 2002 by Tracy Doyle ...
(Date:4/25/2017)... April 25, 2017 Endo International plc (NASDAQ: ... 2017. Members of its senior management team will host a conference ... a.m. ET. The dial-in number to access the ... 509-7598, and the passcode is 6086379. Please dial in 10 minutes ... A replay of the call will be available from May ...
Breaking Medicine Technology: